List of Morphabond Er drug patents
Morphabond Er is owned by Daiichi Sankyo Inc.
Morphabond Er contains Morphine Sulfate.
Morphabond Er has a total of 2 drug patents out of which 0 drug patents have expired.
Morphabond Er was authorised for market use on 02 October, 2015.
Morphabond Er is available in tablet, extended release;oral dosage forms.
The generics of Morphabond Er are possible to be released after 12 August, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314788 | DAIICHI SANKYO INC | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) | |
| US7955619 | DAIICHI SANKYO INC | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 02 October, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic